Company news: K-V Pharmaceutical and Ther-Rx

Share this article:
In a blow to K-V Pharmaceutical, the FDA said it will not take action against pharmacies that make hydroxyprogesterone caproate, the active ingredient in K-V's recently approved pre-term labor prevention drug Makena. K-V had sent a letter to pharmacists indicating that the agency will no longer allow them to make or compound the injectable drug. “This is not correct,” said FDA in a statement, adding it would not pursue enforcement unless the compounded products are unsafe, of substandard quality or are not compounded according to standards. K-V's branded drug subsidiary Ther-Rx started promoting Makena in March.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.